Clinical Trials Sponsored by Peking University Cancer Hospital and Institute

Total 6844 results

Peking University Cancer Hospital & Institute

Unknown

Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System

Gastrointestinal Neoplasms

China
Peking University Cancer Hospital & Institute

Completed

Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients (DCCIK)

Breast Neoplasms | Neoplasm Metastasis

China
Peking University Cancer Hospital & Institute

Unknown

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Hyper-ERAS Program for Highly Selective Colorectal Cancer Patients

Colorectal Cancer | ERAS

China
Peking University Cancer Hospital & Institute

Recruiting

Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer

Rectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab (BRAND)

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Registry Study in MSI/dMMR Solid Tumors

Solid Tumor | MSI-H | DMMR Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Colorectal Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy

Advanced Malignant Neoplasm

China
Peking University Cancer Hospital & Institute

Not yet recruiting

To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases

Colorectal Liver Metastases (CRCLM)

China
Peking University Cancer Hospital & Institute

Recruiting

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

Colorectal Liver Metastases

China
Peking University Cancer Hospital & Institute

Recruiting

The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

China
Peking University Cancer Hospital & Institute

Recruiting

Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma

Gastric Cancer | Gastric Adenocarcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer (CTAC)

Colon Cancer | Circulating Tumor DNA

China
Peking University Cancer Hospital & Institute

Recruiting

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Recruiting

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Solid Tumor

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma

Positron-Emission Tomography
Peking University Cancer Hospital & Institute

Recruiting

Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas

PET/MRI

China
Peking University Cancer Hospital & Institute

Recruiting

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab (HELP)

HER2-positive Metastatic Breast Cancer | Previously Treated With Trastuzumab | Trastuzumab Combined With Pertuzumab and Chemotherapy

China
Peking University Cancer Hospital & Institute

Recruiting

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Not yet recruiting

Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis

Melanoma Stage IV
Peking University Cancer Hospital & Institute

Recruiting

The Performance of Multi-tracer Multimodality PET in Lymphoma

Positron-Emission Tomography

China
Peking University Cancer Hospital & Institute

Recruiting

Research for the Molecular Imaging of the HER2 Targeting Tracer

HER2 Positive or Suspicious Positive Tumors

China
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Peking University Cancer Hospital & Institute

Completed

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Colorectal Cancer | Surgery | Liver Metastases | Minimal Residual Disease | Circulating Tumor DNA

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Research for the Molecular Imaging of the PD-L1 Targeting Tracer

Lung Cancer | Solid Tumor

China
Peking University Cancer Hospital & Institute

Active, not recruiting

PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer

Prostate Cancer

China
Peking University Cancer Hospital & Institute

Active, not recruiting

CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors

Gastrointestinal Cancer

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer

Breast Cancer

China
Peking University Cancer Hospital & Institute

Completed

Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer (MENCA-GC)

Gastric Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Advanced Non-squamous Non-small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Pancreatic Cancer | Gastric Adenocarcinoma | Cholangiocarcinoma | HER2-negative Breast Cancer

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Completed

Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics

Esophagus Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy

QOL; Quality of Life;Gastric Cancer; Gastrectomy;Neoadjuvant Chemotherapy

China
Peking University Cancer Hospital & Institute

Unknown

Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma

Lymphoma | Positron-Emission Tomography | Tumor, Solid

China
Peking University Cancer Hospital & Institute

Unknown

The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Unknown

Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma (BJCH-MM-0624)

Advanced Mucosal Melanoma

China
Peking University Cancer Hospital & Institute

Unknown

A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Docetaxel | Nivolumab

China
Peking University Cancer Hospital & Institute

Unknown

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

Recurrent Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Unknown

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Advanced Melanoma

China
Peking University Cancer Hospital & Institute

Unknown

Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection (HAICAT)

Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Unknown

A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Metastatic Renal Cell Carcinoma

China
Peking University Cancer Hospital & Institute

Completed

Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy

Breast Neoplasms | Neoplasm Metastasis

China
Peking University Cancer Hospital & Institute

Unknown

Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

Melanoma | Neoplasm Metastasis | TOR Serine-Threonine Kinases

China
Peking University People's Hospital
Peking University Cancer Hospital & Institute

Recruiting

Frontline of ASCT in High-risk DLBCL (Essential)

Diffuse Large B Cell Lymphoma

China
Peking University First Hospital
Peking University Cancer Hospital & Institute

Recruiting

Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients

Pain, Postoperative | Breast Neoplasms | Chronic Pain | Dexmedetomidine | Mastectomy | Prognosis | Nerve Block

China

Clinical Trials Sponsored by Peking University Cancer Hospital and Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations